KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Revenue: 2009-2024

Historic Revenue for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $16.5 billion.

  • Teva Pharmaceutical Industries' Revenue rose 3.42% to $4.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $16.8 billion, marking a year-over-year increase of 0.02%. This contributed to the annual value of $16.5 billion for FY2024, which is 4.40% up from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Revenue stood at $16.5 billion for FY2024, which was up 4.40% from $15.8 billion recorded in FY2023.
  • In the past 5 years, Teva Pharmaceutical Industries' Revenue ranged from a high of $16.7 billion in FY2020 and a low of $14.9 billion during FY2022.
  • Over the past 3 years, Teva Pharmaceutical Industries' median Revenue value was $15.8 billion (recorded in 2023), while the average stood at $15.8 billion.
  • Its Revenue has fluctuated over the past 5 years, first dropped by 6.00% in 2022, then climbed by 6.17% in 2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' Revenue (Yearly) stood at $16.7 billion in 2020, then decreased by 4.69% to $15.9 billion in 2021, then dropped by 6.00% to $14.9 billion in 2022, then increased by 6.17% to $15.8 billion in 2023, then climbed by 4.40% to $16.5 billion in 2024.